HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[The fibrillarin (Scl-34) autoantibody in systemic scleroderma].

Abstract
Reexamination of ANA positive sera with nucleolare fluorescence staining on HEp-2 cells and hamster liver imprints revealed 3 sera with an uniform characteristic pattern. It is characterized by: 1. Strong clumpy fluorescence of nucleoli in the interphase. 2. Missing nucleoplasma staining (pure nucleolar). 3. Characteristic granular staining of the cytoplasma from the condensed chromosoma in mitosis. 4. Additive fluorescence of a nucleolus-like body. 5. Extremely high antibody titers. 6. Negative immunodiffusion. This nucleolar staining pattern was described by Bernstein et al. as a clumpy nucleolar pattern. It is produced through an antibody to the dense fibrillar component of the nucleolus (fibrillarin). This antigen is a protein of the U3 RNP with a molecular weight 34 kDa. Clinically is the fibrillarin antibody highly specific for systemic scleroderma especially with diffuse skin involvement. We found it in 1% of scleroderma patients. Its pathogenetic importance is not known.
AuthorsG Kühn, M Jarzabek-Chorzelska, M Blaszczyk, T P Chorzelski, S Jablonska
JournalDermatologische Monatschrift (Dermatol Monatsschr) Vol. 176 Issue 1 Pg. 19-26 ( 1990) ISSN: 0011-9083 [Print] Germany
Vernacular TitleDer Fibrillarin-(Scl-34-) Autoantikörper bei der systemischen Sklerodermie.
PMID2178987 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antibodies, Antinuclear
  • Chromosomal Proteins, Non-Histone
  • fibrillarin
Topics
  • Antibodies, Antinuclear (analysis)
  • Cell Nucleolus (immunology)
  • Chromosomal Proteins, Non-Histone (immunology)
  • Fluorescent Antibody Technique
  • Humans
  • Molecular Weight
  • Scleroderma, Systemic (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: